Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

Treatments and trials you qualify for
Education for your stage of care
Financial support for your medications
Solutions to your side effects

Know Your Myeloma Immunotherapy: Teclistamab and other Bispecifics

Name: Know Your Myeloma Immunotherapy: Teclistamab and other Bispecifics
Start: 2023-08-16T13:00:00-04:00
End: 2023-08-16T14:00:00-04:00

Aug 16, 2023

01:00PM - 02:00PM EDT

Online Event

Overview

Teclistamab is one of the newcomers to the myeloma treatment world, and certainly one that's getting a lot of attention. As the first bi-specific antibody treatment approved to fight myeloma, it's now being combined with other bi-specifics, compared to the vastly successful CAR T, and proving itself to be an exciting, effective myeloma drug.

Learn more about its mechanism of action, clinical trial results, and what its future might be in our upcoming webinar!

Agenda

1:00 PM

Introductions

Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr. Gurbakhash Kaur.

1:05 PM

Presentation

Dr. Gurbakhash Kaur

Dr. Gurbakhash Kaur talks about its mechanism of action, clinical trial results.

1:35 PM

Questions and Answers

Audience

Type your questions in the chat and we will answer them!

Speakers & Moderators

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Dr. Gurbakhash Kaur

Gurbakhash Kaur, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She specializes in stem cell transplantation, immunotherapy, CAR T-cell therapy, and treating patients with multiple myeloma and other plasma cell disorders, including amyloidosis and Waldenström macroglobulinemia. She is also involved in clinical trials to develop novel therapeutics for multiple myeloma. Dr. Kaur earned her medical degree at Drexel University College of Medicine. She completed a residency in internal medicine at Tufts Medical Center and received advanced training in hematology and oncology through a fellowship at Montefiore Medical Center. Certified by the American Board of Internal Medicine in medical oncology and in hematology, she joined the UT Southwestern faculty in 2020. Dr. Kaur’s clinical and research interests include improving outcomes for patients with hematologic malignancies, particularly multiple myeloma, by developing newer cellular and immunotherapy therapies, and she publishes and delivers presentations on her work regularly. She is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the International Myeloma Society, among other professional organizations.